The book “Contemporary Management of Myeloproliferative Neoplasms” provides an overview of the diagnostic classification of the MPN with relevant examples. Overview of relevant contributors to disease pathogenesis is given that provide a background and rationale for the later chapter on novel MPN therapies, especially for myelofibrosis (MF). Because thrombotic and bleeding complications can dominate the clinical course during the first decade of disease in essential thrombocythemia (ET) and polycythemia vera (PV), an entire chapter is devoted toward the epidemiology, pathogenic features, risk factors, and management of this set of complications. Epidemiology, clinical features, prognosis, and treatment of ET, PV, and MF are provided. Impact of JAK2 V617F mutation is discussed in chapter 5. Relevant data on prognosis, conditioning regimens, and outcomes of transplantation and diagnosis and treatment of patients with mast cell diseases and hypereosinophilic disorders is highlighted. In addition, update on management of these BCR-ABL negative MPNs is provided.